Table 2.
Up-titration patterns in patients initiating vericiguat
|
Total (n = 2129) |
Women (n = 565) |
Men (n = 1423) |
Age tertile 1: 20–69 years (n = 716) |
Age tertile 2: 70–81 years (n = 732) |
Age tertile 3: ≥ 82 years (n = 681) |
|
|---|---|---|---|---|---|---|
| First observed dose (“starting dose”) | ||||||
| 2.5 mg | 1792 (84.2%) | 477 (84.4%) | 1198 (84.2%) | 603 (84.2%) | 615 (84.0%) | 574 (84.3%) |
| 5 mg | 254 (11.9%) | 68 (12.0%) | 167 (11.7%) | 86 (12.0%) | 92 (12.6%) | 76 (11.2%) |
| 10 mg | 83 (3.9%) | 20 (3.5%) | 58 (4.1%) | 27 (3.8%) | 25 (3.4%) | 31 (4.6%) |
| Maximal dose reached | ||||||
| 2.5 mg | 652 (30.6%) | 158 (28.0%) | 444 (31.2%) | 201 (28.1%) | 230 (31.4%) | 221 (32.5%) |
| 5 mg | 708 (33.3%) | 213 (37.7%) | 448 (31.5%) | 245 (34.2%) | 228 (31.1%) | 235 (34.5%) |
| 10 mg | 769 (36.1%) | 194 (34.3%) | 531 (37.3%) | 270 (37.7%) | 274 (37.4%) | 225 (33.0%) |
| Time (days) until up-titration | ||||||
| to 5 mg | 17.0 (11.0–33.0) | 16.0 (9.0–34.0) | 17.0 (11.0–32.0) | 20.0 (13.0–45.0) | 16.5 (11.0–29.0) | 14.0 (8.0–30.0) |
| to 10 mg | 37.0 (25.0–64.0) | 37.0 (24.5–64.5) | 39.0 (26.0–64.0) | 41.0 (26.0–73.0) | 36.5 (25.0–59.0) | 34.0 (24.0–55.0) |
Data are n (%) or median (quartiles)